Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Chava, Perry"'
Publikováno v:
HemaSphere, Vol 7, p e60805b6 (2023)
Externí odkaz:
https://doaj.org/article/c4bd4e3b1a054b9295f29923ccc669b4
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 471-474 (2022)
Abstract Patients with lymphoproliferative diseases are at high risk for SARS‐CoV‐2‐related complications and mortality. The role of casirivimab and imdevimab (REGEN‐COV), a neutralizing antibody cocktail, to treat immunocompromised hemato‐
Externí odkaz:
https://doaj.org/article/6c270e70ac324e938a13feae8c0f7fcd
Autor:
Ron Ram, Sigal Grisariu, Liat Shargian-Alon, Odelia Amit, Yaeli Bar-On, Polina Stepensky, Moshe Yeshurun, Batia Avni, David Hagin, Chava Perry, Ronit Gurion, Nadav Sarid, Yair Herishanu, Ronit Gold, Chen Glait-Santar, Sigi Kay, Irit Avivi
Publikováno v:
Haematologica, Vol 107, Iss 5 (2021)
Data regarding efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in the elderly, geriatric population are insufficient. In 2019, tisagenlecleucel and axicabtagene-ciloleucel were commercially approved for relapsed/refractory d
Externí odkaz:
https://doaj.org/article/ee6304dbe547454693562f57a4f69b46
Autor:
Yamit Shorer Arbel, Ben-Zion Katz, Ronen Gabizon, Amit Shraga, Yotam Bronstein, Talia Kamdjou, Anat Globerson Levin, Chava Perry, Irit Avivi, Nir London, Yair Herishanu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Proteolysis targeting chimeras (PROTACs) are small molecules that form ternary complexes between their target and E3 ligase, resulting in ubiquitination and proteasomal degradation of the target protein. Using our own designed Bruton’s tyrosine kin
Externí odkaz:
https://doaj.org/article/650b70fb17db4836a1e4c93f379c112c
Autor:
Albert Kolomansky, Irit Kaye, Nathalie Ben-Califa, Anton Gorodov, Zamzam Awida, Ofer Sadovnic, Maria Ibrahim, Tamar Liron, Sahar Hiram-Bab, Howard S. Oster, Nadav Sarid, Chava Perry, Yankel Gabet, Moshe Mittelman, Drorit Neumann
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting
Externí odkaz:
https://doaj.org/article/8fe13af2d8c84491be39e81d8606f215
Autor:
Shamir Geller, Sigi Kay, Eran Ellenbogen, Tomer Goldsmith, Shoshi Bar-On, Emily Warshauer, Varda Deutsch, Eli Sprecher, Chava Perry, Ilan Goldberg
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 13, p adv00171 (2020)
Abstract is missing (Short communication)
Externí odkaz:
https://doaj.org/article/ff105eb7b0e74d208c05f04a1f87272c
Autor:
Efrat Luttwak, Yafit Segman, May Saban, Odit Gutwein, Irit Avivi, Chava Perry, Alina Filiavich, Nadav Sarid
Publikováno v:
Journal of Medical Screening. 29:255-259
Objective To determine the rate of lymphoproliferative disease (LPD) in women undergoing routine breast cancer screening (BCS). BCS can reveal pathologies other than carcinoma that involve the breast and lymph tissue. The few studies that have descri
Autor:
Ofrat Beyar-Katz, Chava Perry, Yael Bar On, Odelia Amit, Odit Gutwein, Ofir Wolach, Rotem Kedar, Oleg Pikovsky, Irit Avivi, Ronit Gold, Jonathan Ben-Ezra, David Shasha, Ronen Ben Ami, Ron Ram
Publikováno v:
Annals of Hematology. 101:1769-1776
Anti CD-19 chimeric antigen receptor T (CAR-T) cells demonstrate effective early anti-tumor response; however, impaired hematopoietic recovery is observed in about 30% of patients with prolonged cytopenia appearing as an unmet need for optimal treatm
Autor:
Ofrat Beyar Katz, Chava Perry, Sigal Grisariu‐Greenzaid, Dana Yehudai‐Ofir, Efrat Luttwak, Batia Avni, Tsila Zuckerman, Inbal Sdayoor, Polina Stepensky, Shimrit Ringelstein‐Harlev, Yael Bar‐On, Diana Libster, Liat Sharvit, Odelia Amit, Uri Greenbaum, Ronit Gold, Yair Herishanu, Noam Benyamini, Irit Avivi, Ron Ram
Publikováno v:
European Journal of Haematology.
Autor:
Irit Avivi, Chava Perry, Yafit Segman, Odelia Amit, Yaeli Bar-On, Ofrat Beyer Katz, Ronit Gold, Elena Ribakovsky, Abraham Avigdor, Vladimir Vainstein, Neta Goldschmidt, Shimrit Ringelstein-Harlev, Netanel A. Horowitz, Odit Gutwein, Ronit Gurion, Gilad Itchaki, Uri Abadi, Anatoly Nemets, Orit Sofer, Miri Vezker, Tamar Tadmor, Najib Dally, Kalman Filanovsky, Merav Leiba, Nadav Sarid, Noam Benyamini, Efrat Luttwak, Yair Herishanu, Ron Ram
Publikováno v:
Annals of Hematology. 101:755-762
Polatuzumab (Pola)-based regimens and chimeric antigen receptor T (CAR T) cells provide superior outcome compared to conventional chemoimmunotherapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). Choosing between thes